We're proud to receive a 2025 CDMO Leadership Award in the “Small Molecule Dosage Form - Global" category.
This poster discusses a stepwise Quality-by-Design (QbD) approach consistent with ICH Q8 (R2) and associated regulatory guidelines to build quality into a Novel ALS drug product.